Search results

With an IPO, not only the company but also the leadership team goes public; in particular the Chairman, the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO). Interest in the company and the behavior of the management gains a new dimension in terms of public attention. This is why it is so important to take a close look at corporate governance and related topics regarding public

Roivant Sciences was founded in New York by a young investor and entrepreneur, Vivek Ramaswamy. In 2016, the company opened its global headquarters in Basel, Switzerland. Sascha Bucher, Head Basel Roivant Pharma and Head of Global Transactions, talks with Switzerland Global Enterprise about his company’s game-changing business model and why Basel is the perfect place to be.  

Breakthroughs, scientific or medical, can transform industries, especially in an environment as dynamic as biotech. To take full advantage of the opportunities, you have to be prepared, and you must have the flexibility to change established procedures, business models and regulatory frameworks.

Globally, investments in the biotech sector are soaring. The ever increasing and aging global population, together with a wide range of unmet medical needs and new technologies that offer more targeted treatment options, are creating global business opportunities that attract ever more players.

This year’s patent analysis builds on the work presented in the Swiss Biotech Report 2018 and drills deeper into specific biotechnology subsets, including the red (health and medicine), white (industrial) and green (agriculture) biotech categories, as well as established and emerging biotechnology subsets.

The biotechnology sector includes a wide array of technologies and applications, with a significant share of Swiss players. Under the umbrella of NTN Swiss Biotech, biotechnet Switzerland together with the Swiss Biotech Association (SBA) has been instrumental in generating private-public partnerships to support the biotechnology area.

The Zurich-based company InSphero has successfully completed a joint project with the University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences (School of Life Sciences FHNW) to develop a 3D organ-on-a-chip assay that can predict the metabolic stability of pharmaceutical drugs. The year-long project was part-funded by Innosuisse, the Swiss Innovation Agency and the

Research funded by the public should be, as far as possible, publicly accessible and free of charge. The Swiss National Science Foundation (SNSF) is committed to the global project of open science.